ELN Leukemias CMPD Publications  · 

Publications

1. Barbui T, Finazzi G: When and how to treat essential thrombocythemia
   N Engl J Med 2005; 353: 85-6
   Subjects: CMPD
2. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, Gisslinger H, Griesshammer M, Hasselbalch H, Kusec R, Le Bousse-Kerdiles MC, Liberato NL, Marchetti M, Reilly JT, Thiele J: European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
   Blood 2005 Oct 15;106(8):2849-53
   Subjects: CMPD
3. Barosi G, Hoffman R: Idiopathic myelofibrosis
   Semin Hematol 2005; 42: 248-58
   Subjects: CMPD
4. Finazzi G, Barbui T: Risk-adapted therapy in essential thrombocythemia and polycythemia vera
   Blood Rev 2005; 19: 243-52
   Subjects: CMPD
5. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T: Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
   Blood 2005; 105: 2664-70
   Subjects: CMPD
6. Finazzi G, Harrison C: Essential Thrombocythemia
   Semin Hematol 2005; 42: 230-8
   Subjects: CMPD
7. Griesshammer M; Heimpel H; Pearson TC: Essential thrombocythemia and pregnancy
   Leuk Lymphoma Sep;22 Suppl 1:57-63 [0008951773]
   Subjects: CMPD
8. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G, Lengfelder E, Reiter A, Chase AJ, Cross NCP: Minimal molecular response in polycythemia vera patients treated with imatinib or interpheron alpha
   Blood December 13, 2005 [doi:10.1182]
   Subjects: CMPD
9. Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.-C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A., Cross, N.C.P: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
   Blood 106, 2162-2168, 2005
   Subjects: CMPD
10. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    J Clin Oncol 2005; 23: 2224-32
    Subjects: CMPD
11. Marchioli R, Finazzi G, Marfisi RM, Tognoni G, Barbui T: Clinical trials in myeloproliferative disorders: looking forward
    Semin Hematol 2005; 42: 259-65
    Subjects:
12. Reiter, A. , Walz, C., Watmore, N., Schoch, C., Blau, I.,Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J.A., Vanstraelen, D., Barker, H.F., Taylor, P.C., O'Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.-J., Hochhaus, A., Hehlmann, R., Chase, A., Cross, N.C.P: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
    Cancer Research 65, 2662-2667, 2005
    Subjects: CMPD